Variants of the CYP11B2 gene predict response to therapy with candesartan

Jan R Ortlepp; Peter Hanrath; Vera Mevissen; Gerhard Kiel; Martin Borggrefe; Rainer Hoffmann

doi:10.1016/s0014-2999(02)01766-1

Variants of the CYP11B2 gene predict response to therapy with candesartan

Eur J Pharmacol. 2002 Jun 7;445(1-2):151-2. doi: 10.1016/s0014-2999(02)01766-1.

Authors

Jan R Ortlepp¹, Peter Hanrath, Vera Mevissen, Gerhard Kiel, Martin Borggrefe, Rainer Hoffmann

Affiliation

¹ Medical Clinic I, University Hospital of Aachen, Pauwelsstrasse 30, 52057 Aachen, Germany. jrortlepp@ukaachen.de

PMID: 12065207
DOI: 10.1016/s0014-2999(02)01766-1

Abstract

In a prospective trial, patients with an elevated diastolic blood pressure (above 95 mm Hg) received high-dose (16 mg) or low-dose (8 mg) candesartan in addition to standardised medication. A positive response to treatment was defined as a diastolic blood pressure <85 mm Hg at follow-up. Genotyping for two candidate genes was performed in 116 patients. Genotypes of the CYP11B2 promotor polymorphism significantly predicted a positive response to treatment (CC: 67%; TC: 34%; TT: 21%; p=0.005).

Publication types

Clinical Trial
Clinical Trial, Phase III
Randomized Controlled Trial

MeSH terms

Aged
Analysis of Variance
Benzimidazoles / therapeutic use*
Biphenyl Compounds
Chi-Square Distribution
Cytochrome P-450 CYP11B2 / genetics*
Female
Humans
Hypertension / drug therapy
Hypertension / enzymology
Hypertension / genetics
Male
Middle Aged
Predictive Value of Tests
Prospective Studies
Tetrazoles / therapeutic use*

Substances

Benzimidazoles
Biphenyl Compounds
Tetrazoles
Cytochrome P-450 CYP11B2
candesartan